Bill
S 809
Requires state health plans and MassHealth to cover biomarker testing used to guide diagnosis and treatment, with 72-hour prior-authorization and guideline-based care.
Status summary
- Introduced in the Massachusetts Senate by Sen. Jacob R. Oliveira on 2/27/2025 (Senate Docket No. 532). Referred to committee(s); reported favorably by committee on 6/23/2025 and referred to the committee on Health Care Financing. Hearing(s) were scheduled in April 2025. The bill was later noted as substituted by A1026 in committee records.
- Note: some metadata provided with the request (alternate titles/sponsors and other federal‑style text) appear inconsistent with the Massachusetts bill text; the legislative language below reflects the text filed in the Massachusetts General Court for S.809.
Main purpose and intent
- Require state-regulated health coverage to provide access to medically supported biomarker testing so that patients receive appropriate, evidence‑based diagnostic or therapeutic information to guide treatment decisions (e.g., precision medicine / gene-based drug interactions).
Key definitions (as set out in the bill)
- "Biomarker": objectively measured indicators of normal/pathologic processes or pharmacologic responses, including gene mutations and protein expression.
- "Biomarker testing": analysis of tissue, blood, or other biospecimens for biomarkers; expressly includes single-analyte tests, multiplex panels, protein expression assays, whole exome/genome/transcriptome sequencing.
- "Consensus statements" and "nationally recognized clinical practice guidelines" are defined to require transparent methodology, multidisciplinary development, and conflict‑of‑interest policies.
Primary provisions and changes
- Chapter 32A (state employees’ group insurance): inserts a new Section 17R requiring the Group Insurance Commission to provide coverage for biomarker testing for active and retired Commonwealth employees covered under GIC plans, according to criteria in the bill.
- Chapter 118E (Massachusetts medical assistance/insurer provisions): inserts a new Section 10M with parallel definitions and coverage requirements (text is truncated in the provided file but mirrors Section 17R structure).
- Coverage criteria: biomarker testing must be covered for diagnosis, treatment selection, management, or monitoring when supported by medical/scientific evidence, including (but not limited to):
- FDA labeled indications for an FDA‑approved/cleared test;
- Tests indicated for an FDA‑approved drug;
- Warnings/precautions on FDA drug labels;
- CMS National Coverage Determinations or Medicare Administrative Contractor (MAC) Local Coverage Determinations.
- Coverage implementation: must align with nationally recognized clinical practice guidelines and consensus statements and be administered to limit care disruptions (e.g., avoid unnecessary repeat biopsies).
- Prior authorization timelines: carriers or utilization review organizations must approve/deny prior authorization requests or appeals and notify the enrollee, provider, and requester within 72 hours; if delay poses significant health risk, decision within 24 hours. If no response in required time, the request/appeal is deemed granted.
- Appeals/exceptions: requires clear, readily accessible processes (including posting on carrier websites) for patients and prescribing practitioners to request exceptions or challenge adverse utilization review determinations.
Who is affected
- Covered patients: state employees and retirees covered under the Group Insurance Commission (Chapter 32A) and enrollees/beneficiaries governed by provisions added to Chapter 118E (MassHealth/related programs).
- Payers/carriers and utilization review organizations: required to update coverage policies and prior authorization processes to meet timelines and transparency standards.
- Providers and clinical laboratories: increased access to testing and potential changes to ordering/authorization workflows.
- Potential downstream effects for private insurers and market norms if standards are adopted more broadly.
Procedural/timing notes
- Introduced 2/27/2025; referred to Financial Services/Finance committee; reported favorably 6/23/2025 and referred to Health Care Financing. Hearings occurred or were scheduled in spring 2025. Legislative record shows S.809 was substituted by A1026 (a companion or substitute bill) — readers should consult the companion/house bill (A1026) for the most current language and status.
Potential impacts (practical considerations)
- Clinical: could expand timely access to precision diagnostics that guide therapy selection, reduce ineffective treatments, and support personalized care.
- Administrative: may require carriers to revise medical policy, prior authorization processes, and IT/website disclosures.
- Fiscal: the bill does not specify budgetary offsets; broader coverage could increase short‑term utilization and costs for tests while potentially lowering costs by avoiding ineffective therapies—an actuarial analysis would be needed.
For more information
- Consult the full bill text (S.809 / Senate Docket No. 532) and substitute A1026 for final enacted language and up‑to‑date status; review committee reports and any fiscal notes prepared by Health Care Financing.
Compiled from official sources — confirm details with the bill’s official record.
Sign in to ask a question.
